Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 9/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 5/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13175023 | 0.90 | DAGLA (0.39) | HDAC1HDAC8HDAC6DAGLAFBP1 | |
| SCHEMBL800880 | 0.90 | DAGLA (0.39) | HDAC1HDAC8HDAC6DAGLAFBP1 | |
| SCHEMBL801034 | 0.86 | HDAC1 (0.42) | HDAC1HDAC8HDAC6C3AR1 | |
| SCHEMBL13174722 | 0.83 | PPARD (0.41) | HDAC1HDAC8HDAC6DAGLA | |
| SCHEMBL800915 | 0.82 | C3AR1 (0.46) | C3AR1 | |
| SCHEMBL800750 | 0.82 | C3AR1 (0.46) | C3AR1 | |
| SCHEMBL15214456 | 0.78 | DAGLA (0.39) | HDAC1HDAC8HDAC6DAGLAFBP1 | |
| SCHEMBL7324378 | 0.78 | DAGLA (0.40) | HDAC1HDAC8HDAC6DAGLAFBP1 | |
| SCHEMBL800494 | 0.77 | KMT2A (0.48) | C3AR1 | |
| SCHEMBL3511397 | 0.77 | KMT2A (0.48) | C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | HDAC1 474/4885HDAC8 812/4885HDAC6 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.